Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.
about
Terlipressin versus other vasoactive drugs for hepatorenal syndromeTerlipressin for hepatorenal syndromeCreatinine Change on Vasoconstrictors as Mortality Surrogate in Hepatorenal Syndrome: Systematic Review & Meta-AnalysisAlbumin administration in the acutely ill: what is new and where next?Treatment and management of ascites and hepatorenal syndrome: an updateSystematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1.Protecting the Kidney in Liver Transplant Candidates: Practice-Based Recommendations From the American Society of Transplantation Liver and Intestine Community of Practice.Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials.Albumin treatment regimen for type 1 hepatorenal syndrome: a dose-response meta-analysis.Revision and update on clinical practice guideline for liver cirrhosis.Improving survival in decompensated cirrhosisHepatorenal syndrome: the 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.Terlipressin and albumin for type 1 hepatorenal syndrome: does bacterial infection affect the response?AISF-SIMTI position paper: the appropriate use of albumin in patients with liver cirrhosis.Hyponatremia and Hepatorenal SyndromePopulation Based Trends in the Incidence of Hospital Admission for the Diagnosis of Hepatorenal Syndrome: 1998-2011.Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives: Chapter 5 Human Albumin - RevisedPredictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics.Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1.Acute kidney injury in cirrhosis.Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study.Terlipressin in hepatorenal syndrome: a systematic review and meta-analysisManagement and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program.Investigational vasopressin receptor modulators in the pipeline.Treatment of hepatorenal syndrome.Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome.Poor outcomes with treatment of hepatorenal syndrome type 1 with splanchnic vasoconstrictors and albumin: report of seven cases and review of the literature.Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials.Terlipressin in hepatorenal syndrome.Management of hepatorenal syndrome in patients with cirrhosis.Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications.Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II).Cirrhotic ascites review: Pathophysiology, diagnosis and management.Albumin in chronic liver disease: structure, functions and therapeutic implications.Comparative efficacy of vasoconstrictor therapies for type 1 hepatorenal syndrome: a network meta-analysis.Hepatorenal syndrome in cirrhosis: diagnostic, pathophysiological, and therapeutic aspects.Emerging hepatic syndromes: pathophysiology, diagnosis and treatment.Therapeutic alternatives for the treatment of type 1 hepatorenal syndrome: A Delphi technique-based consensus.Treatment to improve acute kidney injury in cirrhosis.
P2860
Q24188350-C2412B92-E550-4789-ADCC-15F2355BB832Q24200336-8A598911-2215-437D-9CC7-1158471BA39FQ26795734-EDFAB3E5-ECF5-40FF-B3F0-38F755FF57B2Q26853626-758B054D-3702-4ED8-BD55-CA698BCAC72DQ27000268-223BBE25-4203-4DFB-A908-1B2B7E63204DQ30239846-4D9D2F2D-6723-45CD-A959-E4CFE3647EB4Q30251763-C2FB8A18-E059-4284-BB01-AF6E38755875Q33698303-30BB136A-A9CE-4F29-B03D-A917BB29BA20Q35654104-F3DCCAE0-D633-4C05-B4B8-954658896E4AQ35852815-E8D7FF2B-3FA5-4A03-8943-C480D414FB7CQ35890613-51767D18-C87D-45D7-A8CC-4EB33F84A30DQ36090423-0CBE1A88-4AFA-4913-BE1C-7E144CDB9E35Q36093575-DD4C0882-A0B7-4151-B6C5-82EC36B18353Q36400103-AF28DFD7-6CC0-4B1C-BB57-984C8093830AQ36515680-6750EDD6-4B07-41D6-9081-BFF35C98A8BFQ36812531-5A234ECE-8A56-4B23-B31F-35525647CEF8Q36814530-659074C2-3B7D-4786-8AC4-7DE3A6CF19CDQ37045780-F85B33C0-5872-42DF-B130-7D6D4AAD7BDAQ37058079-5748A91E-AF33-4D33-BCB5-6EDAC5255F09Q37141412-51778191-6008-4CDB-BF5F-CDFA40E99C67Q37323711-70A99867-00C4-4091-B201-ECFF9A37557FQ37429032-891C39A6-38DC-412F-81E1-7F38D65D31A7Q37438171-ACF3ED2E-E311-4E01-AEB9-1AF8EF935EB8Q37489472-8F560EDF-8408-470B-AFB3-7C4BFD7BCFDAQ37546110-D29A4704-0B9F-420B-98E3-77BAD16ED569Q37605883-B22B6CFD-E60B-4EAC-9283-AFC134C73BCDQ37626627-A76C4471-EB79-4EC2-9D01-D40D3F513D0CQ37634026-A669A90D-62F8-46D8-A41B-AE2C06F31D87Q37674956-5722163A-6D93-4432-99EB-7AE89DD3EEBAQ37850887-19715CB1-8F9B-4B6C-9827-B699C41D78F3Q37913980-0EB6DCA6-60D9-4F39-936A-67531993B612Q38083035-17A23F88-08AB-4223-A8D6-8A8EDDC71D5EQ38098443-8131CB78-E2A7-4CCC-8E8C-0898E9587990Q38110291-3D982D34-B58A-487E-BA3A-21D8FF58A991Q38595462-3832C9B4-AF63-4E0E-800B-D4874414F9B5Q38679099-354D7B16-DA81-49AB-A608-AA5B0C8607DAQ38850006-BD608F36-23F5-4634-95C8-04F47B8AE3D2Q38858262-7A0F4F9D-7AFB-4EC6-9B48-FA68B767E4F1Q38962412-8D1136E3-1C05-4B7F-B426-0A93F70007C0Q39029019-46187DDB-092E-4807-B27A-C3B9B73E448D
P2860
Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.
@en
Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.
@nl
type
label
Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.
@en
Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.
@nl
prefLabel
Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.
@en
Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.
@nl
P2093
P50
P1476
Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome
@en
P2093
Bruno M Cosimo
Davide Pulvirenti
Luca Ignaccolo
Sebasiano Siringo
P2888
P304
P356
10.1007/S10620-007-9919-9
P577
2007-10-16T00:00:00Z